- Home
- NXC vs NSPR Comparison
NXC vs NSPR Comparison
Compare NXC & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- NSPR
- Stock Information
- Founded
- NXC 1992
- NSPR 2005
- Country
- NXC United States
- NSPR United States
- Employees
- NXC N/A
- NSPR N/A
- Industry
- NXC Investment Managers
- NSPR Medical/Dental Instruments
- Sector
- NXC Finance
- NSPR Health Care
- Exchange
- NXC Nasdaq
- NSPR Nasdaq
- Market Cap
- NXC 79.3M
- NSPR 79.7M
- IPO Year
- NXC N/A
- NSPR N/A
- Fundamental
- Price
- NXC $12.72
- NSPR $2.50
- Analyst Decision
- NXC
- NSPR Strong Buy
- Analyst Count
- NXC 0
- NSPR 2
- Target Price
- NXC N/A
- NSPR $4.50
- AVG Volume (30 Days)
- NXC 17.5K
- NSPR 53.1K
- Earning Date
- NXC 01-01-0001
- NSPR 05-09-2025
- Dividend Yield
- NXC 3.97%
- NSPR N/A
- EPS Growth
- NXC N/A
- NSPR N/A
- EPS
- NXC 0.19
- NSPR N/A
- Revenue
- NXC N/A
- NSPR $7,027,000.00
- Revenue This Year
- NXC N/A
- NSPR $27.41
- Revenue Next Year
- NXC N/A
- NSPR $127.08
- P/E Ratio
- NXC $70.47
- NSPR N/A
- Revenue Growth
- NXC N/A
- NSPR 8.49
- 52 Week Low
- NXC $11.86
- NSPR $2.07
- 52 Week High
- NXC $13.70
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- NXC 43.96
- NSPR 50.96
- Support Level
- NXC $12.66
- NSPR $2.42
- Resistance Level
- NXC $12.73
- NSPR $2.60
- Average True Range (ATR)
- NXC 0.12
- NSPR 0.14
- MACD
- NXC -0.02
- NSPR 0.03
- Stochastic Oscillator
- NXC 12.65
- NSPR 78.02
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.